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ABSTRACT
Introduction: Micro-invasive glaucoma
surgical implantation of trabecular micro-
bypass stents, previously shown to be safe and
effective for open-angle glaucoma (OAG)
subjects during cataract surgery, was
considered for evaluation as a sole procedure.
The aim of this study was to evaluate the safety
and intraocular pressure (IOP)-lowering efficacy
after ab interno implantation of two Glaukos
Trabecular Micro-Bypass iStent inject second
generation devices in subjects with OAG. This
study was performed at sites in France,
Germany, Italy, Republic of Armenia, and
Spain.
Methods: In this pan-European, multi-center
prospective, post-market, unmasked study, 99
patients with OAG on at least two topical ocular
hypotensive medications who required
additional IOP lowering to control glaucoma
disease underwent implantation of two GTS400
stents in a stand-alone procedure. Patients were
qualified if they presented with preoperative
mean IOP between 22 and 38 mmHg after
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medication washout. Postoperatively, subjects
were assessed at Day 1, Months 1, 3, 6, 7, 9, and
12. IOP, medication use and safety were
assessed at each visit.
Results: Sixty-six percent of subjects achieved
IOP B18 mmHg at 12 months without
medication, and 81% of subjects achieved
Month 12 IOP B 18 mmHg with either a single
medication or no medication. Mean baseline
washout IOP values decreased by 10.2 mmHg or
39.7% from 26.3 (SD 3.5) mmHg to 15.7 (SD 3.7)
mmHg at Month 12. Mean IOP at 12 months
was 14.7 (SD 3.1) mmHg in subjects not using
ocular hypotensive medications. Reduction
from preoperative medication burden was
achieved in 86.9% of patients, including 15.2%
with reduction of one medication and 71.7%
with reduction of two or more medications.
Postoperative complications occurred at a low
rate and resolved without persistent effects.
Conclusion: In this series, implantation of two
trabecular micro-bypass second generation
stents in subjects with OAG resulted in IOP
and medication reduction and favorable safety
outcomes.
Keywords: Ab interno; Intraocular pressure;
iStent inject; Open-angle glaucoma;
Ophthalmology; Trabecular bypass
INTRODUCTION
Glaucoma, the second leading cause of blindness
in the world, requires chronic, life-long
treatment with an array of therapeutic options
available including medications, laser treatment
and surgical implants [1, 2]. The common
therapeutic goal of surgical treatment for this
progressive and debilitating disease is to lower
intraocular pressure (IOP) to target levels to
prevent loss of visual field, while enabling
patients to recover faster and with fewer
complications [2]. An ideal procedure for the
treatment of open-angle glaucoma (OAG) would
restore physiologic outflow and decrease IOP
using a minimally invasive approach.
Limitations and safety considerations of the
multitude of therapies has prompted the
development of a safer, less invasive treatment
for glaucoma designed to prevent the need for
trabeculectomy or other invasive procedures
associated with significant damage to
intraocular and extraocular structures and
resulting significant postoperative
complications.
The advent of micro-invasive glaucoma
surgery (MIGS) using ab interno trabecular
micro-bypass stents has been shown to be safe
and effective for mild–moderate glaucoma
subjects in conjunction with cataract surgery
[3–5]. These stents bypass the trabecular
meshwork, which is considered the primary
source of resistance to aqueous drainage in
many glaucomas, in order to improve outflow
through the natural physiologic pathway and
reduce IOP [3, 6–8]. MIGS has the potential to
preserve important eye tissue and future
treatment options that may help maintain
long-term vision for the patient with
glaucoma [9]. The first generation iStent
Trabecular Micro-Bypass (Glaukos Corp.,
Laguna Hills, CA, USA) has demonstrated the
capability of providing a safe and effective way
to lower IOP in patients with mild-to-moderate
glaucoma. Multiple studies have demonstrated
long-term safety and effectiveness of iStent in
conjunction with or without cataract surgery to
reduce IOP and medication burden for up to
5 years postoperative [3–5, 10–12].
A new micro-scale stent, the Model GTS400
iStent inject (Glaukos Corporation, Laguna Hills,
CA, USA), is a second generation device
developed to reduce IOP in a safe and effective
way, similar to that of the iStent. The iStent
190 Adv Ther (2014) 31:189–201
inject is CE marked in Europe. Recent work by
Bahler et al. [13, 14] entailed a prospective
laboratory investigation using the iStent inject
in human donor eyes and found that the
addition of a second stent further increased
outflow facility beyond the initial increase from
placement of the first stent, a finding consistent
with their work on the first generation stent. In
parallel to the investigation of multiple stent
insertion, an initial injector system, the Model
G2-0 injector (Glaukos Corporation), was
designed to enable implantation of iStent
inject devices one at a time. A second
generation injector, the Model G2-M-IS system
(Glaukos Corporation), was then developed to
house two stents, providing the clinician the
ability to insert multiple stents while entering
the eye only once.
The goal of this work was to examine
outcomes after implantation of multiple
trabecular bypass stents in OAG by increasing
conventional outflow, and to determine the
additive effect of a drug to increase uveoscleral
outflow if needed to further reduce IOP. This
report summarizes data from patients who
underwent implantation of the second
generation GTS-400 iStent inject device via
either the Model G2-0 injector or the Model
G2-M-IS Injector as a sole procedure.
METHODS
Subject Screening and Inclusion
This prospective, open-label study involved
iStent implantation and follow-up of phakic or
pseudophakic subjects with OAG (including
primary, pigmentary, and pseudoexfoliative)
on at least two topical ocular hypotensive
medications, who in the opinion of the
investigator, required additional IOP lowering
to control their OAG. The study was conducted
at sites in France, Germany, Italy, Republic of
Armenia, and Spain. A list of participating
investigators and site affiliation is provided in
Appendix 1 in the Electronic Supplementary
Material. Appendix 2, in the Electronic
Supplementary Material, lists the number of
subjects at each site. The study protocol was
approved by ethical committees at each of the
study sites. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2000 and 2008. Informed consent was
obtained from all patients for being included in
the study. The clinical trial registration number
is NCT00911924 (Clinicaltrials.gov).
Inclusion criteria included subjects at least
18 years of age who had been using at least two
IOP-lowering medications for at least 3 months
but still required additional IOP lowering, with
visual field defects or nerve abnormality
characteristic of glaucoma, preoperative best
corrected visual acuity (BCVA) of 20/200 or
better, and ability and willingness to provide
informed consent and attend follow-up visits
through 1 year postoperative. Subjects were
required to have an untreated mean IOP of at
least 22 mmHg and \38 mmHg at screening
baseline visit after washout of medications.
Exclusion criteria included subjects known to
be non-responders to latanoprost and with
glaucoma other than OAG, angle closure
glaucoma, secondary glaucoma (except
pseudoexfoliative and pigmentary), eyes with
prior stent or shunt implantation, argon laser
trabeculoplasty or selective laser trabeculoplasty
within 90 days of screening visit, peripheral
anterior synechiae, prior iridectomy or laser
iridotomy, active corneal inflammation or
edema, prior corneal surgery, corneal
opacities/disorders inhibiting visualization of
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the nasal angle, elevated episcleral venous
pressure, and chronic or active ocular
inflammation.
Following the informed consent process, a
comprehensive screening examination was
performed that included best corrected visual
acuity (BCVA), slit-lamp biomicroscopy,
indirect ophthalmoscopy, and measurement of
IOP (Goldmann applanation). At most sites, IOP
measurements were taken by the same operator
using the same tonometer each time.
Tonometers were calibrated monthly.
Subjects selected for the trial began a
washout of all glaucoma medications (4 weeks
for prostaglandin analogs and beta-blockers,
2 weeks for alpha adrenergic agonists and
carbonic anhydrase inhibitors). At baseline,
the subjects’ BCVA (via Early Treatment of
Diabetic Retinopathy Study system [15]), cup-
to-disc ratio (C:D), central corneal thickness and
IOP were measured. Un-medicated diurnal IOP
measurements were taken at selected sites at
8 am, 10 am, 12 pm, and 4 pm (±1 h).
iStent Inject Device
The micro-bypass iStent inject device GTS400 is
a single-piece, heparin-coated, gamma-sterilized
device made from implant-grade titanium. The
one-piece device is 360 lm in length, and the
maximal width of the conical head is 230 lm.
The stent is symmetrically designed such that it
may be used in either the right or left eye. The
iStent inject is smaller than the first generation
iStent, but functions in the same way to bypass
the trabecular meshwork to improve aqueous
flow from the anterior chamber into Schlemm’s
canal. The iStent inject devices are pre-loaded in
the customized injector system designed to
deliver the stents automatically into
Schlemm’s canal through a stainless steel
insertion tube. The injector features a surgeon-
activated release button on the housing, which
is pressed to allow the stent to move over a
small guiding trocar to exit the injector. The
G2-0 injector housed one stent; therefore, two
injectors were used during implantation. The
G2-M-IS system houses two stents, thereby
enabling insertion of both stents from one
injector. A diagram of the iStent inject is
presented in Fig. 1.
Surgery and Follow-up
Two iStent inject devices were implanted
through the trabecular meshwork into
Schlemm’s canal at the nasal position,
separated by approximately two clock hours,
Fig. 1 Trabecular Micro-Bypass Stent Model GTS400
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using topical anesthesia and stent insertion
methods similar to those described previously
[16]. Following implantation of two iStents,
subjects received topical postoperative anti-
inflammatory and anti-infective medications
for 4 weeks.
Follow-up visits were scheduled at Day 1,
Months 1, 3, 6, 7, 9, and 12. Postoperative
examination parameters were similar to
preoperative parameters. In addition,
postoperative diurnal IOP was measured at
selected sites at Month 6, Month 9, and
Month 12 exams at the same time points
(8 am, 10 am, 12 pm, and 4 pm) as the
baseline exam. At Month 6, subjects whose
IOP was greater than or equal to 18 mmHg were
prescribed latanoprost for the next 6 months.
The study protocol further indicated that if at
any time during the study, a subject’s IOP
exceeded 38 mmHg, the subject would be
exited from the study and alternative
treatment commenced at the discretion of the
investigator.
Study Endpoints and Statistical Analysis
The primary efficacy endpoint was defined as
the proportion of subjects with IOP of
B18 mmHg without the use of ocular
hypotensive medications at Month 12. The
secondary efficacy endpoint was defined as the
proportion of subjects with IOP B 18 mmHg
regardless of ocular hypotensive medications
at Month 12. Subjects not included in the
responder analysis at Month 12 either did not
have IOP data available at Month 12 or
underwent secondary surgical intervention
that could affect IOP (e.g., incisional or laser
surgery, cataract surgery, or postoperative
procedure to reposition or remove the stent)
prior to Month 12. Safety analyses involved
assessment of adverse events, BCVA, slit lamp
findings, and pachymetry.
The subject population in this trial included
qualified subjects who underwent implantation
of two GTS-400 iStent inject devices with either
insertion device, the G2-0 injector or the G2-M-
IS system. The safety and efficacy data comprise
all study subjects (regardless of insertion device)
because the implanted stents are identical in all
cases. For the primary and secondary efficacy
endpoints, proportional analyses were
performed. Exact 95% confidence intervals
based on a binomial distribution were
calculated for the responder rates. For
continuous variables such as mean IOP and
IOP reduction, 95% confidence intervals were
computed using the t-distribution. Statistical
tests were performed using PC-SAS software
(version 9.1.3, SAS Institute Inc., Cary, NC,
USA).
RESULTS
Subject Disposition and Demographics
A total of 112 subjects were enrolled in the
study. One subject did not have baseline
information recorded and eight subjects did
not have at least two medications at screening.
Four enrolled subjects did not undergo
implantation of two devices. These 13 subjects
Table 1 Subject accountability
Subject status Screening Baseline Day 1 Month 1 Month 3 Month 6 Month 7 Month 9 Month 12
All implanted eyes
Available at visit 99 99 98 91 96 93 87 93 92
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were not included in the analysis, resulting in a
total of 99 subjects analyzed. This group of 99
subjects consisted of 72 cases in which the G2-0
injector was employed, while the remaining 27
cases underwent insertion via the G2-M-IS
system. Of the 99 subjects implanted with
devices, 92 subjects were available at the
Month 12 visit and 7 subjects did not
complete the Month 12 visit (Table 1).
Another 4 subjects had undergone secondary
surgical interventions by the Month 12 visit.
Therefore, data from 88 subjects were included
in the analysis of efficacy endpoints.
Demographics for the study population are
presented in Table 2. The mean age at
enrollment was 66.4 years ± 10.9 (SD). Fifty-six
subjects (57.0%) were female. There were 40
right eyes and 59 left eyes. Eight-two eyes
(83.0%) were phakic. The mean C:D ratio was
0.7 ± 0.2 (SD). Subjects were taking an average
of 2.21 medications; with beta-blockers used in
80.8% of eyes, followed by prostaglandin
analogs (61.6% of eyes), carbonic anhydrase
inhibitors (56.6%), alpha agonists (18.2%), and
miotics (pilocarpine; 4.0%). Mean medicated
IOP at screening was 22.1 mmHg ± 3.3 (SD) and
mean IOP following medication washout was
26.3 mmHg ± 3.5 (SD).
Intraocular Pressure and Medication Use
The primary endpoint, IOP B 18 mmHg at
12 months without medications, was achieved
by 66% of subjects (n = 58 of 88 eyes; 95% CI
55%, 76%; Table 3). The secondary endpoint,
IOP B 18 mmHg at 12 months regardless of
medications was achieved by 81% of subjects
(n = 71 of 88 eyes; 95% CI 71%, 88%), of which
12 subjects were using a prostaglandin at Month
12. Furthermore, 72% of subjects (n = 63, 95%
CI 61%, 81%) experienced a 20% or greater
reduction in IOP without medication at
12 months, 93% (n = 82, 95% CI 86%, 97%)
experienced a 20% or greater reduction in IOP
regardless of medication at 12 months, and 77%
Table 2 Demographic and preoperative characteristics
Variable Statistics
Subjects analyzed (N) 99















Mean C:D ratio ± SD 0.7 ± 0.2
Mean # medications (SD) 2.21 (0.44)
# Medications by classa
Alpha agonist 18 (18.2%)
Beta blocker 80 (80.8%)
Carbonic anhydrase inhibitor 56 (56.6%)
Prostaglandin analog 61 (61.6%)
Miotic (pilocarpine) 4 (4.0%)
Mean medicated IOP (mmHg) 22.1 ± 3.3
Mean pachymetry (lm) 541.0 ± 38.1
Mean post-washout IOP (mmHg) 26.3 ± 3.5
C:D cup:disc ratio, IOP intraocular pressure
a Subjects could be on two or more medications
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(n = 68, 95% CI 67%, 86%) achieved IOP
reduction of 30% or more.
Mean IOP at the 6-month visit was
16.8 ± 4.1 mmHg (95% CI 15.9, 17.7; Table 4).
At this visit, 24.4% (n = 23) were administered
medication for additional IOP control. By the
12-month visit, mean IOP was
15.7 ± 3.7 mmHg (95% CI 14.9, 16.5) in all 88
subjects, representing a 10.2 mmHg or 39.7%
decrease from baseline washout IOP. Mean IOP
at Month 12 was 14.7 ± 3.1 mmHg (95% CI
14.0, 15.5) in the 66 subjects not using ocular
hypotensive medication. At Month 12, 86.9%
of subjects had reduced their medication
burden, including 15.2% with reduction of
one medication, and 71.7% with reduction of
two or more medications (53.5% reduced by 2,
17.2% reduced by 3, and 1% reduced by 4
medications, respectively).
Best Corrected Visual Acuity, Slit-Lamp,
Pachymetry
The proportion of subjects with BCVA of 20/40
or better was 84% at screening, 84% at 1 and
3 months, 88% at 6 months and 86% at
12 months (Table 5). The mean C:D ratio at
Month 12 was 0.7 ± 0.2, and did not change
versus preoperative C:D ratio. Mean central
corneal thickness was stable over time as well
with 541.4 ± 38.1 lm reported at screening
versus 537.0 ± 35.3 lm at 12 months.















n (%) 95% CIa
N (IOP available) 99 91 96 93 87 93 92
N 99 91 94 89 82 88 88
IOP B 18 mmHg
without Meds
0 (0%) 61 (67%) 62 (66%) 54 (61%) 61 (74%) 63 (72%) 58 (66%)
(55%, 76%)
IOP B 18 mmHg
regardless of Meds
















63 (69%) 68 (72%) 62 (70%) 66 (80%) 71 (81%) 68 (77%)
(67%, 86%)
SSIb 0 0 2 4 5 5 4
IOP intraocular pressure, SSI secondary surgical intervention
a Diurnal IOP was taken for the visit at selected sites
b SSI related to glaucoma. Outcomes after SSI were excluded
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Postoperative Adverse Events and Other
Observations
Eighteen ocular adverse events were reported
(Table 6). Ten of these adverse events were
elevated IOP. Elevated IOP resolved in four
subjects after treatment with medication, and
in six subjects after surgical intervention,
including two trabeculectomies and one
goniotrephanation. Three reports of stent
obstruction resolved without treatment, and
three reports (in conjunction with elevated IOP
reported above) resolved after laser surgery
[neodymium-doped yttrium aluminum garnet
(Nd:YAG) laser in two cases and argon laser in
one case]. Following resolution of stent
obstruction in one subject, this subject
underwent subsequent deep sclerectomy for a
subsequent event of elevated IOP. The
remaining five adverse events consisted of one
subject with progression of pre-existing cataract
treated with cataract surgery, one subject with
an allergic reaction due to ocular hypotensive
medication, a subject with stent malposition,
one subject with intraocular inflammation, and
a subject with sub-conjunctival hemorrhage. All
cases of adverse events resolved without further
sequelae. There were 13 cases in which one of
the stents was not visible, one case of
goniosynechiae (resolved with laser


















N (IOP available) 99 99 91 96 93 87 93 92
Nb 99 99 91 94 89 82 88 88
Mean 22.1 26.3 17.0 16.6 16.8 15.8 15.5 15.7
SD 3.3 3.5 6.4 4.5 4.1 3.2 3.0 3.7
95% CI 21.5, 22.8 25.7, 27.0 15.7, 18.4 15.7, 17.6 15.9, 17.7 15.1, 16.5 14.9, 16.1 14.9, 16.5
Min 16.0 22.3 6.0 10.0 10.0 10.0 10.8 9.8
Max 33.0 38.2 38.0 38.0 29.8 30.0 28.0 29.5
Mean IOP—eyes without medication at Month 12
IOP
N 74 74 66 71 67 65 66 66
Mean 22.2 25.6 15.0 15.5 15.8 15.0 14.5 14.7
SD 3.4 3.0 5.1 3.8 3.8 2.3 2.3 3.1
95% CI 21.4, 22.9 24.9, 26.3 13.8, 16.2 14.6, 16.4 14.9, 16.8 14.4, 15.5 14.0, 15.1 14.0, 15.5
Min 16.0 22.3 6.0 10.0 10.0 10.0 10.8 9.8
Max 33.0 38.2 30.0 27.0 24.8 21.0 20.0 23.3
IOP change from baseline—eyes without medication at Month 12
N 74 74 66 71 67 65 66 66
Mean -10.8 -10.0 -9.5 -10.4 -10.6 -10.4
SD 4.8 3.9 3.5 3.0 3.1 3.2




-10.3, -8.6 -11.1, -
9.6
-11.4, -9.9 -11.2, -9.6
Min -21.2 -25.2 -17.8 -19.0 -19.8 -18.3
Max 2.3 0.0 -2.0 -4.3 -4.3 -1.5
IOP intraocular pressure, SSI secondary surgical intervention
a Diurnal IOP was taken for the visit at selected sites
b Outcomes after SSI were excluded
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treatment), and one case of lens–iris synechiae
(resolved without surgical intervention). No
associated complications were reported. Two
subjects presented with posterior capsular
opacification and associated BCVA loss that
resolved after Nd:YAG capsulotomy.
DISCUSSION
Previous investigations have concluded that
MIGS procedures are capable of improving
aqueous outflow through the natural
physiologic pathway without compromising
safety for patients with glaucoma. In the US
Food and Drug Administration pivotal trial of the
first generation iStent, Samuelson et al. [3]
reported a mean IOP reduction of 8.4 mmHg at
12 months following implantation of a single
iStent in conjunction with cataract surgery. In a
follow-up report by Craven et al. [5], Month 24
mean IOP in the iStent group was
17.1 ± 2.9 mmHg on a mean of 0.3 ± 0.6
medications. Fea et al. [4, 12] and Arriola-
Villalobos et al. [10] corroborated the long-term
postoperative IOP reduction after implantation
of one stent. Confirmation of the outcomes of
implantation of a single first generation iStent for
the reduction of IOP prompted the investigation
of the use of two iStent devices to provide
increased facility-of-outflow and to achieve
further reductions in IOP. Work by Belovay
et al. [17] showed the benefit of multiple
implantation of stents in conjunction with
cataract surgery to reduce mean IOP to less than
15 mmHg while also reducing medication
burden through a period of 12 months
postoperative. An initial study demonstrated
that subjects with mild-to-moderate OAG who
were implanted with two iStent devices as a sole
procedure reported an average IOP of
13.6 mmHg at 1 year postoperatively without
the need for ocular hypotensive medication [18,
19]. Further, this study confirmed that IOP
reduction to \15 mmHg and elimination of
medication burden is possible after
implantation of two iStent devices, as a stand-
alone procedure, without significant
postoperative adverse effects. The study
concluded MIGS with iStent to be a safe and
effective implant procedure that supports earlier
intervention in mild-to-moderate OAG [18, 19].
Thus, multiple stent usage has been shown to be
viable, both in a theoretical in vitro perfusion
model [14, 15] and in clinical experience [18, 19].
Table 5 Best corrected visual acuity over time
BCVA Baseline Month 1 Month 3 Month 6 Month 7 Month 9 Month 12
20/20 or better 42 (42%) 35 (39%) 40 (43%) 42 (46%) 43 (50%) 40 (43%) 43 (47%)
20/40 or better 83 (84%) 75 (84%) 79 (84%) 80 (88%) 74 (86%) 80 (86%) 79 (86%)
20/80 or better 93 (94%) 83 (93%) 90 (96%) 87 (96%) 81 (94%) 88 (95%) 88 (96%)
20/100 or better 94 (95%) 85 (96%) 92 (98%) 89 (98%) 83 (97%) 89 (96%) 90 (98%)
20/200 or better 99 (100%) 89 (100%) 94 (100%) 91 (100%) 86 (100%) 92 (99%) 92 (100%)
20/400 or better 99 (100%) 89 (100%) 94 (100%) 91 (100%) 86 (100%) 93 (100%) 92 (100%)
Worse than 20/400 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
N (BCVA available) 99 89 94 91 86 93 92
Baseline last available measurement before implantation, BCVA best corrected visual acuity
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The current post-market, prospective, multi-
center study evaluated the safety and IOP-
lowering efficacy of two GTS-400 iStent inject
devices implanted as a sole procedure. The
study comprised 99 subjects who underwent
implantation of two iStent devices per eye with
either the G2-0 injectors or the G2-M-IS injector
and were followed for 1 year. To our knowledge,
this is the first prospective multi-centered study
of iStent inject implantation as the sole
procedure in eyes with open-angle glaucoma.
The merits of the data include, among other
factors, a high rate of subject follow-up through
1 year (93%; n = 92/99).
This study in subjects with OAG on two or
more preoperative medications showed mean
IOP reduction through 1 year. Most subjects
reported IOP B 18 mmHg without the use of
concomitant medication. With IOP
reduction C 30% in 61% of subjects without
medication and in 77% of subjects regardless of
medication, it is shown that the Preferred
Practice Pattern goal of 25% IOP reduction
from pre-treatment baseline [2] was achieved in
the majority of subjects in this study. The
medication reduction from preoperative use
was noteworthy. Furthermore, the IOP-
lowering effect of two iStent inject devices
implanted as a sole procedure in this study
appears to be greater than that of a single iStent
implanted in conjunction with cataract surgery.
The iStent US pivotal trial of iStent found that
66% of treatment eyes versus 48% of control
eyes achieved C20% IOP reduction without
medication at Month 12 (P = 0.003) [3].
Results from the current study compare
favorably: 72% achieved C20% IOP reduction
without medication at Month 12, and 93% the
Month 12 IOP reduction of 20% or more
regardless of medication.
Table 6 Postoperative ocular adverse events and other
postoperative observations
n (N5 99) Percent
(%)
Adverse event
Elevated IOP 10 10.1
Treated with medication 4 4.1
Treated with surgerya 3 3.0
With stent obstruction and
treated with laser surgeryb
3 3.0
Stent obstruction 3 3.0
Progression of pre-existing
cataract treated with cataract
surgery
1 1.0
Allergic reaction to ocular
hypotensive medication
1 1.0
Stent malposition 1 1.0
Intraocular inﬂammation 1 1.0
Sub-conjunctival hemorrhage 1 1.0
Other postoperative observations













Nd:YAG neodymium-doped yttrium aluminum garnet,
IOP intraocular pressure
a One subject underwent trabeculectomy, one subject
underwent trabeculectomy and cataract surgery, and one
subject underwent goniotrephanation
b Two subjects underwent Nd:YAG laser surgery and one
subject underwent argon laser surgery. Following
resolution of stent obstruction, a subsequent event of
elevated IOP in one subject was subsequently treated with
deep sclerectomy
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A secondary goal of our study was to evaluate
the potential additive effect of conventional
outflow and uveoscleral outflow therapy. While
66% of subjects met both the primary endpoint
of IOP B18 mmHg at 12 months without
medication and subsequently the secondary
endpoint (i.e., Month 12 IOP B 18 mmHg
regardless of medications), an additional 15%
(n = 13) of subjects met the secondary endpoint
with the use of a single medication, in whom 12
subjects were using prostaglandins. This
suggests an additive (synergistic) effect of
prostaglandin added to conventional outflow
therapy. It should be noted that the second
generation iStent inject devices studied in the
trial described in this report are implanted using
an automated injector system versus the
manual inserter system for the first generation
device, and may be preferred by some clinicians.
Further, this study shows that the iStent inject
can lower IOP independent of cataract
extraction.
The study demonstrated an acceptable safety
profile with a low number of subjects
experiencing adverse events. No subjects
experienced hypotony, endophthalmitis, or
sight-threatening complications frequently
associated with more invasive procedures.
Other safety measures including BCVA,
C:D ratio, and pachymetry were stable
throughout the 1-year postoperative period.
Limitations of this trial were that it was not
masked, did not require a two-person method
(with one person masked) to measure IOP, did
not have diurnal IOP data available at all sites,
did not include visual field measurements, and
did not include a control group. There was no
standard protocol for restarting glaucoma
therapy except at the 6-month time point.
These limitations will be addressed in future
studies.
CONCLUSION
This present study demonstrated that
implantation of two trabecular micro-bypass
stents as the sole procedure in subjects with
OAG has a favorable benefit/risk profile as
demonstrated by the proportion of subjects
who reported IOP reduction and B18 mmHg
without medication through 12 months. The
iStent inject is able to provide a clinically
significant reduction in intraocular pressure
with a favorable safety profile. Further studies
of this promising MIGS technology are planned
for evaluation in phakic and pseudophakic OAG
patients with earlier glaucoma disease and in
concomitant cataract procedures.
ACKNOWLEDGMENTS
Study devices were provided by Glaukos
Corporation, Laguna Hills, CA, USA. Sponsorship
for performing this study and payment of the
article processing charges was provided by
Glaukos Corporation. Editorial assistance in the
preparation of this manuscript was provided by
Jeannie Gifford Cecka, Clinical and Regulatory
Consultant, and was funded by Glaukos
Corporation. L. Voskanyan is the guarantor for
this article, and takes responsibility for the
integrity of the work as a whole.
Conflict of interest. L. Voskanyan received
financial support from Glaukos for her work as
an investigator in this study. J. Garcı´a-Feijoo´
received financial support from Glaukos for his
work as an investigator in this study. J.I. Belda
received financial support from Glaukos for his
work as an investigator in this study. A. Fea
received financial support from Glaukos for his
work as an investigator in this study and has
Adv Ther (2014) 31:189–201 199
also received non-study financial support from
Glaukos. A. Ju¨nemann received financial
support from Glaukos for his work as an
investigator in this study. C. Baudouin
received financial support from Glaukos for his
work as an investigator in this study.
Compliance with ethics guidelines. The
study protocol was approved by ethical
committees at each of the study sites. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Resnikoff S, Pascolini D, Etya’ale D, et al. Global
data on visual impairment in the year 2002. Bull
World Health Organ. 2004;82:844–51.
2. American Academy of Ophthalmology Glaucoma
Panel. Preferred Practice Pattern guidelines.
Primary open-angle glaucoma. San Francisco, CA:
American Academy of Ophthalmology; 2010.
Available at: http://www.aao.org/ppp. Last acces-
sed January 6, 2014.
3. Samuelson TW, Katz LJ, Wells JM, Duh Y-J,
Giamporcaro JE, for the US iStent Study Group.
Randomized evaluation of the trabecular micro-
bypass stent with phacoemulsification in patients
with glaucoma and cataract. Ophthalmology.
2011;118:459–67.
4. Fea AM. Phacoemulsification versus
phacoemulsification with micro-bypass stent
implantation in primary open-angle glaucoma.
J Cataract Refract Surg. 2010;36:407–12.
5. Craven ER, Katz LJ, Wells JM, Giamporcaro JE, for
the iStent Study Group. Cataract surgery with
trabecular micro-bypass stent implantation in
patients with mild-to-moderate open-angle
glaucoma and cataract: Two-year follow-up.
J Cataract Refract Surg. 2012;38:1339–45.
6. Grant WM. Experimental aqueous perfusion in
enucleated human eyes. Arch Ophthalmol.
1963;69:783–801.
7. Johnstone MA, Grant WG. Pressure-dependent
changes in structures of the aqueous outflow
system of human and monkey eyes. Am J
Ophthalmol. 1973;75:365–83.
8. Rosenquist R, Epstein D, Melamed S, et al. Outflow
resistance of enucleated human eyes at two
different perfusion pressures and different extents
of trabeculotomy. Curr Eye Res. 1989;8:1233–40.
9. Saheb H, Ahmed II. Micro-invasive glaucoma
surgery: current perspectives and future directions.
Curr Opin Ophthalmol. 2012;23:96–104.
10. Arriola-Villalobos P, Martinez-de-la-Casa J,
Fernandez-Perez J, et al. Combined iStent
trabecular micro-bypass stent implantation and
phacoemulsification for coexistent open-angle
glaucoma and cataract: a long-term study. Br J
Ophthalmol. 2012;. doi:10.1136/bjophthalmol-
2011-300218.
11. Spiegel D, Wetzel W, Neuhann T, et al. Coexistent
primary open-angle glaucoma and cataract: interim
analysis of a trabecular micro-bypass stent and
concurrent cataract surgery. Eur J Ophthalmol.
2009;19:393–9.
12. Fea AM, Pignata, G, Bartoli E, et al. Prospective,
randomized, double-masked trial of trabecular
bypass stent and cataract surgery vs. cataract
surgery alone in primary OAG: long-term data.
Presented at the 2012 European Society of Cataract
and Refractive Surgeons, Milan, Italy, September,
2012.
13. Bahler C, Hann C, Fjield T, et al. Second-generation
trabecular meshwork bypass stent (iStent inject)
increases outflow facility in cultured human
anterior segments. Am J Ophthal. 2012;153:1206–13.
14. Bahler C, Smedley G, Zhou J, Johnson D. Trabecular
bypass stents decrease intraocular pressure in
cultured human anterior segments. Am J Ophthal.
2004;138:988–94.
200 Adv Ther (2014) 31:189–201
15. Early Treatment Diabetic Retinopathy Study.
Manual of operations. Chap. 12, 1985.
16. Arriola-Villalobos P, Martinez de la Casa JM, Diaz-
Valle D, et al. Mid-term evaluation of the new
Glaukos iStent with phacoemulsification in
coexistent open-angle glaucoma or ocular
hypertension and cataract. Br J Ophthalmol.
2013;97:1250–5.
17. Belovay GW, Naqi A, Chan BJ, Rateb M, Ahmed II.
Using multiple trabecular micro-bypass stents in
cataract patients to treat open-angle glaucoma.
J Cataract Refract Surg. 2012;38:1911–7.
18. Katz LJ, on behalf of the MIGS Study Group. IOP
and medication reduction after micro invasive
glaucoma surgery with two trabecular micro-
bypass stents in OAG. Presented at 2013 American
Glaucoma Society Annual Meeting, San Francisco,
CA, February, 2013.
19. Chang LJ, on behalf of the MIGS Study Group.
Intraocular pressure reduction and safety outcomes
after microinvasive glaucoma surgery with 2
trabecular bypass stents in OAG. Presented at
2013 American Society of Cataract and Refractive
Surgeons Annual Meeting, San Francisco, CA, April,
2013.
Adv Ther (2014) 31:189–201 201
